Nonalcoholic Steatohepatitis
Resmetirom for Nonalcoholic Steatohepatitis (NASH)
Resmetirom ( Rezdiffra ) is set to become the first medication approved for treating nonalcoholic steatohepatitis (NASH) with fibrosis in adults . About 5% of adults in the US have NASH. You will start to hear NASH called metabolic dysfunction-associated steatohepatitis (MASH) to reflect its link with cardiometabolic risk factors (diabetes, dyslipidemia, obesity, etc…
قراءة المزيد
Vitamin-E
Guide to manage NONalcoholic fatty liver disease
As a clinical pharmacist, you will see more focus on managing nonalcoholic fatty liver disease (NAFLD) , partly due to new guidelines. It’s being called a “sleeper epidemic” About 1 in 4 patients have this steatosis, but most don’t have symptoms. NAFLD often goes hand in hand with cardiovascular (CV) risk factors, such as insulin resistance or diabetes , obesity an…
قراءة المزيد
Pioglitazone
Consider Actos for NASH patients
As a hospital pharmacist, you will see more nonalcoholic fatty liver disease (NAFLD) . According to studies, up to 100 million Americans have this buildup of fat in the liver. It often goes hand in hand with obesity , dyslipidemia , insulin resistance , and diabetes . About 20% of patients with NAFLD have nonalcoholic steatohepatitis (NASH) , the mo…
قراءة المزيد
Social Plugin